{
    "clinical_study": {
        "@rank": "21875", 
        "arm_group": [
            {
                "arm_group_label": "Trichuris suis ova", 
                "arm_group_type": "Active Comparator", 
                "description": "TSO 2500 x 2 doses every 2 weeks followed by TSO 7500 x 6 doses every 2 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 8 doses every 2 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, 2-arm, placebo-controlled crossover study in pediatric\n      patients with autism spectrum disorder with all patients receiving 16-weeks of TSO treatment\n      and 16 weeks of placebo."
        }, 
        "brief_title": "Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Autism", 
        "condition_browse": {
            "mesh_term": [
                "Autistic Disorder", 
                "Child Development Disorders, Pervasive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients, 5 to 17 years of age\n\n          -  Patients must fulfill DSM-V diagnostic criteria for autism spectrum disorder\n             ascertained at screening, using a clinical review confirmed by the Autism Diagnosis\n             Observation Schedule - Second edition (ADOS-2)\n\n          -  Written informed consent from parent(s) or legal guardian(s) with sufficient\n             intellectual capacity to understand the study and support patients' adherence to the\n             study procedures must be obtained for patients who are not emancipated.  In\n             accordance with Institutional Review Board (IRB) requirements, the patient will\n             complete an informed assent when developmentally appropriate, to participate in the\n             study before conduct of any study-specific procedures.\n\n          -  Patients are able and willing to swallow study medication suspension.\n\n        Exclusion Criteria:\n\n          -  Known diagnosis of syndromal form of Autism (e.g. Rett Syndrome, Childhood\n             Disintegrative Disorder, Fragile X Syndrome, etc.)\n\n          -  Patients who cannot discontinue anti-psychotic medication\n\n          -  Patients with current active seizure disorder or who have had a seizure within the\n             last 6 months prior to screening\n\n          -  Female patient who is pregnant or breastfeeding or wishing to become pregnant during\n             study participation or unwilling to use birth control.\n\n          -  Patients who have received helminthic treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02140112", 
            "org_study_id": "CNDO 201-101"
        }, 
        "intervention": [
            {
                "arm_group_label": "Trichuris suis ova", 
                "intervention_name": "Trichuris suis ova", 
                "intervention_type": "Biological", 
                "other_name": "TSO"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "T. suis ova", 
            "Trichuris suis ova", 
            "Autism Spectrum Disorder", 
            "ASD"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "location": [
            {
                "contact": {
                    "email": "SOberReynolds@autismcenter.org", 
                    "last_name": "Sharman Ober-Reynolds", 
                    "phone": "602-218-8225"
                }, 
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85006"
                    }, 
                    "name": "Southwest Autism Research & Resource Center"
                }, 
                "investigator": {
                    "last_name": "Raun Melmed, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ropa7@earthlink.net", 
                    "last_name": "Elissa Molloy-Plaza", 
                    "phone": "281-893-4111"
                }, 
                "contact_backup": {
                    "email": "ropa20@redoakpsychiatry.com", 
                    "last_name": "Julie Brekke", 
                    "phone": "281 893-4111"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77090"
                    }, 
                    "name": "Red Oak Psychiatry"
                }, 
                "investigator": {
                    "last_name": "Lawrence Ginsberg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A RANDOMIZED, DOUBLE-BLIND, PHASE 2A CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF TRICHURIS SUIS OVA FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER", 
        "overall_contact": {
            "email": "mryan@coronadobio.com", 
            "last_name": "Michael Ryan", 
            "phone": "781-652-4514"
        }, 
        "overall_contact_backup": {
            "email": "awheeler@coronadobio.com", 
            "last_name": "Amy Wheeler", 
            "phone": "781-652-4509"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Aberrant Behavior Checklist - Irritability (ABC-I) at 16 weeks", 
            "safety_issue": "Yes", 
            "time_frame": "36 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02140112"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Coronado Biosciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Coronado Biosciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}